Clinical Research in Emerging Countries- Ready Access to the resources to reduce clinical trials delays.

Clinical Research in Emerging Countries April 3-4, 2006 | Miami, FL | Aggressive financial targets and intense global competition area creating tremendous pressures on pharmaceutical companies to develop and introduce novel therapies as quickly as possible. But at the same time that speed to market is more important than ever, the growing number of potential new drugs entering clinical development increases competition for the finite numbers of subjects and investigators available in the most popular locations for clinical trials: US, Canada and Western Europe. The emerging shortage on clinical resources can significantly delay the start of a trials for many sponsors. To avoid such delays, many pharmaceuticals companies are using or considering alternatives sites in Latin America, Asia and Central and Eastern Europe to conduct a portion of their clinical trials.

Miami, FL (PRWEB) February 9, 2006 -- Intense global competition has created tremendous pressures on pharmaceutical companies to develop and introduce novel drug therapies as quickly as possible. While the need for speed to bring new drugs to market is more important than ever, the growing number of potential new drugs entering the all important clinical trial development stage increases competition for the finite numbers of subjects and investigators available in the most popular locations for clinical trials: North America and Western Europe. The consequent shortage on clinical resources can significantly delay the start of clinical trials for many sponsors thus many pharmaceutical companies have begun to use and contemplate carrying out clinical trials in alternative sites such as Latin America, Asia and Central and Eastern Europe

Through the presentation of case studies and panel discussion the Clinical Research In Emerging Countries Conference April 3-4, 2006 will show the current realities of clinical trials and look at the improvements and opportunities which exist in the Global Market for clinical trial development. Topics of interest include, ‘The Challenges and Opportunities of Conducting Large Global Trials’, Andy Lee, VP Worldwide head of Clinical Study & Data Management, Pfizer Global Research and Development and ‘Assessing the Strategic Benefits of Conducting Clinical Research in Emerging Markets’, Cezary Statuch, Executive Director, Global Development Organization, Bristol Meyers Squibb.

Experts from Astrazeneca, Genzyme, Wyeth, GlaxoSmithKline, SanofiAventis, Albert Einstein Healthcare Network, Xenova Biomedix, Clinstar, Targacept Inc., Nabi Pharmaceuticals, Asperva Pharmaceuticals Corporation, Amgen, Ligand Pharmaceuticals Inc, Boehringer Ingelheim Promeco, Therekos and St. Jude Children’s Research Hospital will share further industry perspectives.

About marcus evans
marcus evans, one of the world’s leading business information companies, is dedicated to the provision of global business intelligence and information to assist in strategic and effective decision-making. Established in 1983, the company’s international network of offices creates major sector-focused events for business learning and networking opportunities across a variety of industries and professions.

For Information Contact:
Keisha Babb | Marketing Manager| 246.417.5413

###